ReviewHepatology communications2018
Management of nonalcoholic fatty liver disease: Lessons learned from type 2 diabetes.
Review in Hepatology communications, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 33 citations in OpenAlex.
- Effects ofJournal of nutrition and metabolism · 2024Review
- Understanding the Burden of Nonalcoholic Fatty Liver Disease: Time for Action.Diabetes spectrum : a publication of the American Diabetes Association · 2024Article
- Prevalence and Crucial Parameters in Diabesity-Related Liver Fibrosis: A Preliminary Study.Journal of clinical medicine · 2023Article
- Article
- Oxidized low-density lipoprotein activates extracellular signal-regulated kinase signaling to downregulate sortilin expression in liver sinusoidal endothelial cells.Journal of gastroenterology and hepatology · 2021Article
- Comparative study of the effects of Abexol and atorvastatin in patients with non-alcoholic fatty liver disease.Clinical and experimental hepatology · 2021Article
- Advanced Liver Fibrosis Is Common in Patients With Type 2 Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening.Diabetes care · 2021Article
- Bariatric Metabolic Surgery Reduced Liver Enzyme Levels in Patients with Non-Alcohol Fatty Liver Disease.Kansas journal of medicine · 2021Article
- Association between anti-acid therapies and advanced fibrosis in type 2 diabetics with biopsy-proven non-alcoholic fatty liver disease.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2020Article
- Metabolic Syndrome and Abnormal Peri-Organ or Intra-Organ Fat (APIFat) Deposition in Chronic Obstructive Pulmonary Disease: An Overview.Metabolites · 2020Review
- Role of Agents for the Treatment of Diabetes in the Management of Nonalcoholic Fatty Liver Disease.Current diabetes reports · 2020Review
- Nonalcoholic fatty liver disease: implications for endocrinologists and cardiologists.Cardiovascular endocrinology & metabolism · 2020Review
- The Role of Insulin Resistance and Diabetes in Nonalcoholic Fatty Liver Disease.International journal of molecular sciences · 2020Review
- Benefits of the Therapy With Abexol in Patients With Non-Alcoholic Fatty Liver Disease.Gastroenterology research · 2020Article
- Guideline-conform statin use reduces overall mortality in patients with compensated liver disease.Scientific reports · 2019Article
- Looking Into the Crystal Ball: Predicting the Future Challenges of Fibrotic NASH Treatment.Hepatology communications · 2019Review
- Current status, problems, and perspectives of non-alcoholic fatty liver disease research.World journal of gastroenterology · 2019Review
- Emerging Pharmacological Targets for the Treatment of Nonalcoholic Fatty Liver Disease, Insulin Resistance, and Type 2 Diabetes.Annual review of pharmacology and toxicology · 2019Review
- Diabetes Mellitus and Risk of Hepatic Fibrosis/Cirrhosis.BioMed research international · 2019Review
- Resveratrol Reduces Glucolipid Metabolic Dysfunction and Learning and Memory Impairment in a NAFLD Rat Model: Involvement in Regulating the Imbalance of Nesfatin-1 Abundance and Copine 6 Expression.Frontiers in endocrinology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nonalcoholic fatty liver disease (NAFLD) is considered the hepatic manifestation of insulin resistance, which is the hallmark of type 2 diabetes (T2D). NAFLD is a known risk factor for developing T2D and has a very high prevalence in those with existing T2D. The diabetes spectrum includes several conditions from prediabetes to T2D to insulin-dependent diabetes leading to macrovascular and microvascular complications. Similarly, NAFLD has a histologic spectrum that ranges from the relatively benign nonalcoholic fatty liver to the aggressive form of nonalcoholic steatohepatitis with or without liver fibrosis to nonalcoholic steatohepatitis-cirrhosis leading to end-stage liver disease. The management of T2D has witnessed significant changes over the past few decades with multiple new drug classes entering the treatment algorithm. Unfortunately, there are no U.S. Food and Drug Administration-approved medications to treat NAFLD, and guidelines for the management of NAFLD are less established. However, the field of drug development in NAFLD has witnessed a revolution over the past 5 years with the establishment of a regulatory pathway for Food and Drug Administration approval; this has generated substantial interest from pharmaceutical companies. Several diabetes medications have been studied as potential treatments for NAFLD with promising results; moreover, drugs that target specific pathways that play a role in NAFLD development and progression are being developed at a rapid pace. Given the similarities between NAFLD and T2D in terms of pathogenesis, underlying risk factors, and disease spectrum, lessons learned from optimizing treatment for T2D can be extrapolated to the management of NAFLD. The aim of this review is to use the founding principles of the comprehensive type 2 diabetes management algorithm to optimize the management of NAFLD. (
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.